GLP-1 diabetic and weight-loss medications slow the stomach emptying
Typical research areas include: In vitro studies using cell lines or isolated islets to measure insulin secretion, beta-cell viability, cAMP signaling, and responses to metabolic stress
Growth is supported by physician oversight, reimbursement schemes, and adherence protocols in regulated health systems
Based on recent studies, SGLT2 inhibitors (SGLTis) are generally considered superior to GLP-1 receptor agonists (GLP-1s) for slowing the progression of chronic kidney disease
Persistent or severe abdominal pain, particularly if it radiates to the back, is the labeled presentation of possible acute pancreatitis
Available from: Accessed: 25 Sep 2025 Heymsfield SB, Coleman LA, Miller R et al (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial